Skip to content

Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years

M. Maccarrone

Frontiers in Molecular Neuroscience May 29, 2017 DOI: 10.3389/fnmol.2017.00166 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Key findings Reports recent advances in anandamide (AEA) metabolism, describing the receptors, metabolic enzymes, and transporters that together drive its biological activity, and highlights open questions still awaiting answers. Argues that a deeper understanding of AEA activity is needed to translate AEA-based drugs into novel therapeutics for human diseases.

Abstract

Cannabis extracts have been used for centuries, but its main active principle ∆9-tetrahydrocannabinol (THC) was identified about 50 years ago. Yet, it is only 25 years ago that the first endogenous ligand of the same receptors engaged by the cannabis agents was discovered. This “endocannabinoid (eCB)” was identified as N-arachidonoylethanolamine (or anandamide (AEA)), and was shown to have several receptors, metabolic enzymes and transporters that altogether drive its biological activity. Here I report on the latest advances about AEA metabolism, with the aim of focusing open questions still awaiting an answer for a deeper understanding of AEA activity, and for translating AEA-based drugs into novel therapeutics for human diseases.

Explore topics